BAYER AG
- Country
- ๐ฉ๐ชGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 243
- Registration Number
- NCT04507061
- Locations
- ๐ซ๐ฎ
Turun yliopistollinen keskussairaala, Turku, Finland
๐ง๐ฌMCOMH Preventsia-2000, Stara Zagora, Bulgaria
๐ฆ๐นZentrum f. klinische Studien Dr. Hanusch GmbH, Wien, Austria
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT04498156
- Locations
- ๐จ๐ฆ
Many Facilities, Multiple Locations, Canada
A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 968
- Registration Number
- NCT04495855
- Locations
- ๐จ๐ณ
Many locations, Multiple Locations, China
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04487431
- Locations
- ๐ณ๐ฑ
PRAHealthSciences, Groningen, Netherlands
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 206
- Registration Number
- NCT04477707
- Locations
- ๐บ๐ธ
John H Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States
๐บ๐ธOffice of Osvaldo A. Brusco, MD, Corpus Christi, Texas, United States
๐บ๐ธJoslin Diabetes Center, Boston, Massachusetts, United States
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT04471337
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 678
- Registration Number
- NCT04464226
- Locations
- ๐บ๐ฆ
Regional communal non-profit enterprise 'Chernivtsi regional clinical hospital' - Urological department, Chernivtsi, Ukraine
๐บ๐ฆMunicipal Non-commercial Enterprise 'City Clinical Hospital #4' of Dnipro City Council - City ?hemotherapy ?enter, Dnipro, Ukraine
๐บ๐ธUrology Centers of Alabama, PC, Homewood, Alabama, United States
Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding
- Conditions
- Interventions
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT04461639
- Locations
- ๐ช๐ธ
Many Locations, Multiple Locations, Spain
Study to Learn About the Effect of Elevit (a Food Supplement Containing Several Vitamins, Minerals, Lutein and DHA) on the Nutrient Content in the Breast Milk and Blood of Women During Breastfeeding Period and on Babies' Physical Growth Parameters
- Conditions
- Interventions
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT04462939
- Locations
- ๐ฉ๐ช
Praxis Fr. Dr. K. Maar, Berlin, Germany
๐ฉ๐ชPraxis Hr. E. Goeckeler-Leopold, Geseke, Nordrhein-Westfalen, Germany
๐ฉ๐ชGynรคkologische Gemeinschaftspraxis Freising, Freising, Bayern, Germany
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 37
- Registration Number
- NCT04454424
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธClinical Pharmacology of Miami, LLC, Miami, Florida, United States